Tempus AI (TEM) Q1 2026: Data Business Jumps 41% as Pharma Demand Deepens

2026-05-05 | By EarningsIQ Research

Tempus AI delivered robust Q1 results, with its data applications segment accelerating to 41% growth and major new pharma partnerships expanding multi-year revenue visibility. The company raised full-year guidance, citing durable demand across oncology diagnostics and a growing pipeline of large-scale data licensing agreements. Management’s commentary signals confidence in sustaining high growth rates, with a diversified business model and expanding market reach underpinning the outlook.

Summary

• Pharma Data Partnerships Scale: Strategic wins with Merck and Gilead reinforce Tempus’s position as a critical data partner for large biopharma.
• Diagnostics Volume Drives Core Growth: Oncology and MRD volumes outpace expectations, offsetting hereditary segment normalization.
• Visibility and Leverage Expand: Multi-year backlog and improved EBITDA trajectory support sustained investment and margin expansion.

Business Overview

Tempus AI operates a precision medicine platform, combining diagnostic testing and data analytics for oncology and other disease areas. The company generates revenue through two primary segments: diagnostics (clinical testing for therapy selection, hereditary risk, and MRD, or minimal residual disease) and data applications (licensing de-identified clinical-molecular data and AI modeling tools to pharma and biotech partners). Its business model leverages a proprietary data asset of over 500 petabytes, powering both clinical decision support and R&D collaborations with major industry players.

Performance Analysis

Tempus AI posted a strong start to 2026, with consolidated revenue up 36% year-over-year, driven by broad-based strength across both diagnostics and data applications. The diagnostics segment, which accounts for the majority of total revenue, grew nearly 35%, propelled by oncology testing volumes (up 28%) and robust demand for both solid tumor and liquid biopsy assays. MRD, though still early in its ramp, delivered outsized percentage growth, highlighting its emerging contribution as reimbursement improves.

The data applications business was the standout, accelerating to 41% year-over-year growth and reaching $87 million in quarterly revenue. This segment’s momentum is anchored by multi-year, nine-figure agreements with leading pharma, including new wins with Merck and a significant expansion with Gilead. Notably, Tempus achieved its third consecutive quarter of $100 million-plus in bookings, with total contract value (TCV) rising and backlog supporting visibility into 2027.

• Data Licensing Durability: Nearly half a dozen pharma partners now license Tempus’s data at $100 million-plus levels, with more in late-stage negotiation, underscoring the stickiness and scale of the platform.
• Diagnostics ASP Tailwind: Average selling prices (ASPs) are expected to rise by $500 per test over the next two years as additional assays receive FDA approval, providing a structural margin lift.
• Cash Flow and EBITDA Leverage: While Q1 free cash flow was negative due to typical seasonality, management expects significant improvement from Q2 onward, with EBITDA guidance raised to $65 million for the year.

Hereditary diagnostics moderated as expected, lapping last year’s exceptional growth, but management projects a return to mid-teens growth in the back half as product launches and market adoption normalize. Overall, Tempus’s diversified revenue streams and expanding backlog underpin its raised full-year outlook and growing margin profile.

Executive Commentary

Strategic Positioning

1. Data Platform Entrenchment in Pharma R&D

Tempus’s data licensing and modeling business is becoming a core infrastructure layer for pharma R&D, with long-term, high-value contracts now the norm for industry leaders. Pharma partners are not just licensing data, but are increasingly co-developing AI models and analytics tools, embedding Tempus deeper into their drug development pipelines. This creates high switching costs and multi-year revenue visibility.

2. Diagnostic Portfolio Expansion and ASP Uplift

FDA approvals for new assays (XT, XR, XF) are set to drive meaningful ASP increases, with management guiding for $500 per test uplift over the next two years. The company’s comprehensive platform—spanning therapy selection, hereditary, and MRD—positions it to capture share across the oncology testing continuum. Algorithmic add-ons (e.g., tumor origin, immune profile) are driving higher attach rates, further differentiating Tempus’s offering and supporting volume growth.

3. Diversification Across Disease Areas and Geographies

While oncology remains the anchor, Tempus is beginning to see traction in other disease areas, such as neurology (e.g., Alzheimer’s multimodal modeling project) and rare diseases. These early wins are small today but represent substantial optionality for future expansion, both in the U.S. and internationally, as the data asset grows in breadth and depth.

4. Operating Leverage and Capital Discipline

Tempus’s EBITDA and cash flow trajectory are inflecting, with management emphasizing a durable improvement in profitability and a strong balance sheet. The company expects quarterly EBITDA to improve sequentially, supported by higher-margin data revenue and normalization of working capital. No additional capital raises are anticipated, underscoring financial self-sufficiency as scale increases.

Key Considerations

The quarter showcased Tempus’s ability to execute on both sides of its business model, with data and diagnostics reinforcing each other and expanding the company’s strategic moat. Several factors warrant investor attention as the year progresses:

Key Considerations:

• Data Backlog Expansion: Sustained TCV growth and multi-year contracts with top pharma provide rare revenue visibility in a typically project-driven sector.
• Diagnostics ASP and FDA Approvals: Each new assay approval directly boosts ASPs and margins, while also supporting broader adoption across clinical workflows.
• Hereditary and Rare Disease Normalization: The hereditary business is expected to rebound to mid-teens growth in H2, while rare disease testing, though small, offers high-ASP, accretive upside.
• MRD Ramp Linked to Reimbursement: Full-scale MRD commercialization is gated by expanded reimbursement, with Personalis partnership providing the near-term path to coverage.
• Operating Leverage Path: Management is confident in sequential EBITDA improvement, with data mix and normalization of payables driving cash conversion through the year.

Risks

Tempus’s outlook is not without risks: Delays in FDA approvals, slower-than-expected reimbursement progress for new assays (especially MRD), or changes in pharma R&D budgets could impact both revenue growth and margin expansion. The data business’s concentration in oncology and a handful of large pharma partners introduces some renewal and pricing risk, though management cites a strong renewal track record. Regulatory changes or competitive advances in AI-driven diagnostics could also alter the long-term growth trajectory.

Forward Outlook

For Q2 and the remainder of 2026, Tempus guided to:

• Revenue in the $1.59 to $1.6 billion range for the full year
• Adjusted EBITDA of approximately $65 million for 2026

Management highlighted several factors that support the raised outlook:

• Strong pipeline and visibility in both data and diagnostics businesses
• Sequential improvement in free cash flow and EBITDA as large contracts shift to quarterly payments and working capital normalizes

Takeaways

Tempus AI’s Q1 results reinforce the company’s emergence as a critical data and diagnostics platform for precision medicine, with durable growth levers and expanding partnerships underpinning a bullish outlook. The company’s multi-segment business model, strong backlog, and improving margin profile differentiate it in a crowded field.

• Data Platform Entrenchment: Pharma’s willingness to sign multi-year, $100 million-plus agreements validates Tempus’s data asset moat and provides rare revenue visibility.
• Diagnostics ASP and Volume Growth: FDA approvals and algorithmic attach rates are set to drive both price and volume, supporting operating leverage and margin gains.
• Optionality in New Disease Areas: Early traction in neurology and rare disease data projects offer long-term growth vectors beyond oncology.

Conclusion

Tempus AI’s Q1 2026 results demonstrate both operational execution and strategic depth, with accelerating data demand, robust diagnostics growth, and improved profitability. The company’s raised guidance and expanding contract backlog signal confidence in sustaining high growth and margin expansion through 2026 and beyond.

Industry Read-Through

Tempus’s performance underscores the secular trend of pharma’s increasing reliance on real-world, multimodal data and AI-driven analytics to accelerate drug development and clinical trial design. The willingness of multiple large pharma to commit to nine-figure, multi-year data agreements suggests that data platforms with scale, breadth, and integrated analytics are emerging as must-have infrastructure for R&D. For diagnostics peers, Tempus’s ability to drive ASP uplift via FDA approvals and algorithmic add-ons highlights the growing importance of comprehensive, workflow-embedded solutions over point products. MRD commercialization remains gated by reimbursement, a theme likely to play out across the sector. Investors should watch for further consolidation of data partnerships and increasing integration of AI tools into both clinical and research settings.

TEM Healthcare Diagnostics Data Licensing Pharma Partnerships AI Modeling Oncology FDA